A growing body of clinical research is pushing the question of psychedelic-assisted therapy from the fringes of medicine into the mainstream — and now it is landing squarely on the NHS’s desk. As BBC News reports, doctors, regulators and politicians are now actively debating whether psilocybin — the active ingredient in magic mushrooms — should be made available as a prescription treatment for depression and other mental health conditions.
The debate is urgent. Millions of people in the UK live with treatment-resistant depression — conditions that don’t respond to conventional antidepressants. Psilocybin, long associated with counterculture and recreation, is now being taken seriously as a potential solution.
What Is Psilocybin and Why Is It Being Considered?
Psilocybin is a naturally occurring psychedelic compound found in certain species of mushroom. When ingested, it is converted in the body to psilocin, which acts on serotonin receptors in the brain — the same pathways targeted by many conventional antidepressants.
What makes it stand out, according to researchers, is speed. Prof David Nutt of Imperial College London — one of the leading figures in psychedelic research — believes psilocybin may be able to “switch off” the part of the brain associated with depression in minutes, rather than the eight weeks it typically takes for antidepressants to take effect.
Clinical trials on depressed patients have indicated that psilocybin may be at least as effective as conventional antidepressants — and potentially with fewer side effects. Since 2022, more than 20 clinical trials have tested psychedelic medicines for conditions including depression, PTSD and addiction.
Who Is Calling for NHS Access?
Prof Oliver Howes, chair of the Royal College of Psychiatrists’ Psychopharmacology Committee, describes psychedelics as a “promising potential new treatment for psychiatric disorders” — including for NHS patients. He is clear that more treatments are urgently needed.
“One of the key messages is that this is something we desperately need — more treatments and better treatments for mental health disorders,” he told the BBC. “These treatments are really interesting because they’ve shown promise in these small-scale studies and have the potential to work quicker.”
Prof Nutt is more direct: “There are so many people suffering unnecessarily. And some of them are dying, because of the unreasonable barriers to research and treatment that we face in this country. It is, in my view, a moral failing.”
At University College London, Dr Ravi Das is currently running trials exploring whether DMT — a short-acting psychedelic — can help heavy drinkers by targeting the brain’s memory and learning systems. He told the BBC: “If psychedelic therapies prove to be both safe and more effective than current treatments, I would hope to see them made accessible via the NHS — rather than to just the privileged few who can afford them privately.”
What Are the Risks?
Not everyone is convinced. A report by the Royal College of Psychiatrists published in September 2025 warned of the potential dangers of psychedelic drugs. Data gathered by the Challenging Psychedelic Experiences Project found that 52% of people who regularly use psychedelics report having had an intensely challenging trip — 39% of whom called it one of the five most difficult experiences of their life.
Jules Evans, director of the project and a university researcher, had a deeply distressing first experience with LSD at 18 that left him with social anxiety, panic attacks and eventually a PTSD diagnosis. He believes doctors and regulators need to understand adverse effects far better before approving any therapies as safe.
An analysis published in the British Medical Journal in November 2024 also raised a methodological concern: because psychedelic treatments are typically combined with psychotherapy, it is difficult to separate the effects of the drug itself from the therapeutic setting — complicating the evaluation of results.
Where Does UK Law Currently Stand?
Psilocybin, DMT, LSD and MDMA are currently classified as Schedule 1 substances in the UK — meaning they are legally considered to have no medicinal value and can only be used in research, under strict and hard-to-obtain medical licences.
The UK medicines regulator, the MHRA, is waiting on results from one of the largest clinical trials to date — led by UK biotech firm Compass Pathways — before deciding whether to relax restrictions. The government has backed plans to ease some licensing requirements for approved clinical trials, and a cross-government working group is coordinating the next steps.
But researchers say progress is painfully slow. “There’s still a lot of red tape holding things up,” said Prof Howes.
Real People, Real Experiences
Behind the clinical debate are real stories. Larissa Hope, an actress who appeared in the TV drama Skins, took psilocybin under clinical supervision as a teenager after conventional antidepressants failed her. She credits it — alongside therapy — with helping her confront suicidal thoughts.
“I had a solid plan to end my life,” she told the BBC. “Then suddenly, death wasn’t the only way. Under psilocybin, my nervous system began, for the first time, to recognise what peace felt like.”
Her story illustrates why this debate matters — and why getting it right is so important.
Source: BBC News — “The debate about whether the NHS should use magic mushrooms to treat depression”, January 2026. Thanks for reading.
